false 0000882291 0000882291 2024-05-24 2024-05-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 24, 2024

 

Aethlon Medical, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada 001-37487 13-3632859

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

 

   

11555 Sorrento Valley Road, Suite 203

San Diego, California

 92121
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (619) 941-0360

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value per share

 AEMD The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

   

 

 

Item 8.01 Other Events.

 

Following our recent financing through a best-efforts public offering, Aethlon Medical, Inc. has 9,229,725 outstanding shares as of the close of business on May 23, 2024.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: May 24, 2024

Aethlon Medical, Inc.

     
     
  By: /s/ James B. Frakes
 

Name:

 

James B. Frakes

Interim Chief Executive Officer and Chief Financial Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 2 

v3.24.1.1.u2
Cover
May 24, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 24, 2024
Entity File Number 001-37487
Entity Registrant Name Aethlon Medical, Inc.
Entity Central Index Key 0000882291
Entity Tax Identification Number 13-3632859
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 11555 Sorrento Valley Road
Entity Address, Address Line Two Suite 203
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code 619
Local Phone Number 941-0360
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol AEMD
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Aethlon Medical (NASDAQ:AEMD)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas Aethlon Medical.
Aethlon Medical (NASDAQ:AEMD)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas Aethlon Medical.